|
Volumn 30, Issue 4, 2000, Pages 684-687
|
Practice guidelines for the management of patients with sporotrichosis
a b c d d d d e e e f f f g g h i i i i more.. |
Author keywords
[No Author keywords available]
|
Indexed keywords
ALLYLAMINE;
AMPHOTERICIN B;
ANTIFUNGAL AGENT;
FLUCONAZOLE;
ITRACONAZOLE;
KETOCONAZOLE;
POLYENE;
PYRROLE DERIVATIVE;
TERBINAFINE;
WOOD;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ARMADILLO;
CAT;
CHILD CARE;
CLINICAL TRIAL;
COMORBIDITY;
COST OF ILLNESS;
DISEASE CLASSIFICATION;
DISEASE SEVERITY;
DISEASE TRANSMISSION;
DRUG EFFICACY;
HIGH RISK POPULATION;
HUMAN;
HYPERTHERMIC THERAPY;
INFECTION PREVENTION;
LUNG INFECTION;
MENINGITIS;
MOSS;
NONHUMAN;
OSTEOARTHROPATHY;
PRACTICE GUIDELINE;
PREGNANCY;
PRIORITY JOURNAL;
REVIEW;
SKIN INFECTION;
SPOROTHRIX SCHENCKII;
SPOROTRICHOSIS;
TREATMENT OUTCOME;
ZOONOSIS;
AIDS-RELATED OPPORTUNISTIC INFECTIONS;
COST-BENEFIT ANALYSIS;
HUMAN;
LUNG DISEASES;
MENINGITIS, FUNGAL;
OUTCOME ASSESSMENT (HEALTH CARE);
SPOROTHRIX;
SPOROTRICHOSIS;
|
EID: 0033800802
PISSN: 10584838
EISSN: None
Source Type: Journal
DOI: 10.1086/313751 Document Type: Review |
Times cited : (210)
|
References (29)
|